Urinary Tract Infections in Pregnancy

Shruti Prabha

Shristi Hospital and Research Center, Boreya, Ranchi, Jharkhand, India.

ABSTRACT
Urinary tract infections are the most common bacterial infections during pregnancy. A history of previous urinary tract infections and low socioeconomic status are risk factor for bacteriuria in pregnancy. *Escherichia coli* is the most common etiologic agent in both symptomatic and asymptomatic infection. Treatment of asymptomatic bacteriuria has been shown to reduce the rate of pyelonephritis in pregnancy and decrease the incidence of low birth weight babies. Therefore, screening for and treatment of asymptomatic bacteriuria has become a standard of obstetrical care.

Keywords: Asymptomatic Bacteriuria, *Escherichia Coli*, Pregnancy, Risk Factor.

INTRODUCTION
Urinary tract infection (UTI) is common in pregnancy. It can be asymptomatic, as well as symptomatic. Hormonal and mechanical changes associated with pregnancy increase the risk of urinary stasis and vesico-ureteral reflux which in conjunction with an already short urethra and difficulty with hygiene due to a distended belly increase the frequency of UTIs in pregnant women. The physiological increase in plasma volume during pregnancy decrease urine concentration and up to 70% pregnant women develop glycosuria, which encourages bacterial growth in the urine. UTI has been reported among 20% of the pregnant women and it is the most common cause of admission in obstetrical wards. The majority of the UTI occur due to ascending infection. Three common clinical manifestations of UTIs (as shown in table 1 below) in pregnancy are: asymptomatic bacteriuria (ASB), acute cystitis and acute pyelonephritis.

Traditionally, the criterion of $10^5$ bacteria/ml has been used, as concentrations at this level represent a chance of contamination of <1%. At concentrations of $10^3$-$10^4$ bacteria/ml there is a 50% chance that contamination is responsible. The only pragmatic solution is to collect midstream samples of urine (MSSUs) after careful decontamination of the urethral meatus.

PATHOGENESIS
Pregnant women develop ureteral dilatation starting in week 6 and peaking during weeks 22 to 24, which persists until delivery (hydronephrosis of pregnancy). Increase in urinary progestogens and estrogens cause relaxation of the ureteric smooth muscle, leading onto dilatation of ureters, which is further aggravated by pressure from the enlarging uterus. This, along with increased bladder volume and decreased bladder tone, contributes to increased urinary stasis and ureterovesical reflux, facilitating bacterial colonization and ascending infection. During pregnancy, the content of amino acids, vitamins and other nutrients is also increased in the urine, further favouring growth of bacteria.

Increasing age, low socioeconomic status and medical interventions, such as catheterization, diabetes mellitus, gestational diabetes and pre-pregnancy UTIs are other risk factors that predispose to UTI during pregnancy.

About 30-40 percent of the asymptomatic bacteriuria cases develop into acute symptomatic UTI. Hence, early detection and timely treatment is crucial to prevent acute pyelonephritis and chronic renal failure in the mother, and to reduce prematurity and fetal mortality in the fetus.

CLINICAL PRESENTATION
Onset in usually acute and presents in the second and third trimesters of the pregnancy.

COMPLICATIONS
Meta-analyses of studies evaluating asymptomatic bacteriuria in pregnancy conclude that there are true associations with preterm delivery and low birthweight. In addition, there are increased risk of pre-eclampsia, anaemia, chorioamnionitis and postpartum endometritis. Fetal risk include fetal growth restriction, stillbirth, perinatal mortality, mental retardation and developmental delay.
Table 1: Classification of urinary tract infection in pregnancy

<table>
<thead>
<tr>
<th>Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic bacteriuria</td>
<td>Defined as persistent colonisation of the urinary tract by significant number of bacteria in women without urinary symptoms.</td>
</tr>
<tr>
<td>Acute cystitis</td>
<td>Distinguished from asymptomatic bacteriuria by the presence of symptoms such as dysuria, urgency, frequency, nocturia, hematuria and suprapubic discomfort in afebrile women with no evidence of systemic illness.</td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td>Defined as significant bacteriuria in the presence of systemic illness and symptoms such as flank or renal angle pain, pyrexia, rigor, nausea and vomiting.</td>
</tr>
</tbody>
</table>

Table 2: Clinical signs and symptoms of UTI

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Fever with rigor and chills</td>
<td>1. Patient is dehydrated and febrile (fever 101°F)</td>
</tr>
<tr>
<td>2. Malaise</td>
<td>2. Costovertebral tenderness</td>
</tr>
<tr>
<td>3. Back pain usually located in the upper lumber area radiating to the groin.</td>
<td>3. Urine is turbid or bloody</td>
</tr>
<tr>
<td>4. Anorexia, nausea and vomiting</td>
<td>4. Tachycardia</td>
</tr>
<tr>
<td>5. Dysuria and frequency of micturition</td>
<td></td>
</tr>
<tr>
<td>6. Uterine contractions</td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Screening for asymptomatic bacteriuria in pregnant women—clinical summary of a US Preventive Service Task Force recommendation statement. 11

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Detection and screening test</th>
<th>Screening intervals</th>
<th>Benefits of detection and early treatment</th>
<th>Harms of detection and early treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screen with urine culture</td>
<td>ASB can be reliably detected through urine culture. The presence of at least 10⁵ colony forming units per ml of urine, of single uropathogen, and in a midstream clean-catch specimen is considered a positive test result.</td>
<td>A clean-catch urine specimen should be collected for screening culture at 12-16 weeks’ gestation or at the first prenatal visit, if later. The optimal frequency of subsequent urine testing during pregnancy is uncertain.</td>
<td>The detection and treatment of asymptomatic bacteriuria with antibiotics significantly reduces the incidence of symptomatic maternal urinary tract infections and low birthweight.</td>
<td>Potential harms associated with treatment of asymptomatic bacterial includes:</td>
</tr>
<tr>
<td>Detection and screening test</td>
<td></td>
<td></td>
<td></td>
<td>• Adverse effects from antibiotics</td>
</tr>
<tr>
<td>Screening intervals</td>
<td></td>
<td></td>
<td></td>
<td>• Development of bacterial resistance</td>
</tr>
</tbody>
</table>

Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.9

Summary Of Recommendations

1. The diagnosis of asymptomatic bacteriuria should be based on results of culture of a urine specimen collected in a manner that minimizes contamination.
   - For asymptomatic women, bacteriuria is defined as 2 consecutive voided urine specimens with isolation of the same bacterial strain in quantitative counts ≥10⁵ cfu/ml.
   - A single, clean-catch voided urine specimen with 1 bacterial species isolated in a quantitative count ≥ 10⁵ cfu/ml identifies bacteriuria in men.

SCRENING AND DIAGNOSIS

A urine culture at the first antenatal visit.8,9 A repeat urine culture should be obtained during the third trimester, because the urine of treated patients may not remain sterile throughout the pregnancy. Infectious Diseases Society of America (IDSA)7 and the US Preventive Services Task Force10,11, also recommend that all pregnant women should undergo screening with urine culture at least once during early pregnancy (12-16 weeks), which is the gold standard for screening of asymptomatic bacteriuria. Routine urinalysis is not adequate as it may give false negative results in bacteriuria without pyuria and false positive results with contamination from vaginal secretions. Diagnosis of asymptomatic bacteriuria is confirmed if two consecutive urine specimens are positive.
• A single catheterized urine specimen with 1 bacterial species isolated in a quantitative count ≥ 10^5 cfu/ml identifies bacteriuria in women or men.

2. Pyuria accompanying asymptomatic bacteriuria is not an indication for antimicrobial treatment.

3. Pregnant women should be screened for bacteriuria by urine culture at least once in early pregnancy, and they should be treated if the results are positive.
   • The duration of antimicrobial therapy should be 3-7 days.
   • Periodic screening for recurrent bacteriuria should be undertaken following therapy.
   • No recommendation can be made for or against repeated screening of culture-negative women in later pregnancy.

4. Screening for and treatment of asymptomatic bacteriuria is recommended before other urologic procedures for which mucosal bleeding is anticipated.

5. Screening for or treatment of asymptomatic bacteriuria is not recommended for the following persons:
   • Premenopausal, non-pregnant women
   • Diabetic women
   • Older persons living in the community
   • Elderly, institutionalized subjects
   • Persons with spinal cord injury
   • Catheterized patients while the catheter remains in situ.

6. Antimicrobial treatment of asymptomatic women with catheter-acquired bacteriuria that persists 48 h after indwelling catheter removal may be considered.

Lumbiganon et al.\textsuperscript{12} observed that a positive dip slide test is very likely to indicate a definitive diagnosis of ASB, whereas a negative result effectively rules out ASB. As for the urine dipstick test, it is currently not appropriate to recommend it for screening ASB in pregnancy due to conflicting results.

Choice of antibiotics should be guided by antimicrobial susceptibility testing whenever possible. The investigators found nitrofurantoin to be the antibiotic of choice for ASB in pregnancy. They recommended that pregnant women with ASB should be treated with a 7-day regimen of antibiotics, although a 1-day regimen might be appropriate in some settings.

**TREATMENT**

**Asymptomatic Bacteriuria**

The treatment schedules are directed by urine culture and sensitivity testing and appropriate antibiotics are continued for at least 7 days. Careful follow-up is necessary to establish urine sterility; some authors advocate repeating MSSUs regularly until delivery.\textsuperscript{13,14} There has been no systematic review of which antibiotic is best for the treatment of asymptomatic bacteriuria. The antibiotic chosen should have a good maternal and fetal safety profile, excellent efficacy and low resistance rates in a given population. Fluoroquinolones have been shown to impair cartilage development in animal studies. Although this adverse effect has not been described in humans, quinolones should be avoided in pregnancy. Tetracycline is not an appropriate agent to use in pregnancy because it leads to discoloration of deciduous teeth if given after 5 months gestation.\textsuperscript{15} Table 4 reviews common antibiotics for asymptomatic and symptomatic lower urinary tract infections.

**Role of Nitrofurantoin in UTIs**

Nitrofurantoin has been in clinical use for many decades now for the treatment of UTIs due to its long record of safety in pregnancy and its bioavailability in urine, making it a good choice.\textsuperscript{22} Moreover, there is no associated R-factor resistance with nitrofurantoin compared to recently introduced antimicrobials.\textsuperscript{23} Also, no significant correlation between nitrofurantoin treatment and fetal malformations has been reported.\textsuperscript{24} All these characteristics make nitrofurantoin a suitable agent for treating bacteriuria in pregnancy.

In a descriptive, cross sectional study in Ibaden, Africa by Awonuga et al., Nitrofurantoin was one of the antibiotics demonstrating high efficacy against uropathogens with antibiotic sensitivity rates between 72.7% and 81.8%.

| Table 4: Common antibiotics for asymptomatic and symptomatic lower urinary tract infections |
|---------------------------------------------|---------------------------------------------|
| **Ampicillin**                              | **Advantages**: No β-lactam antibiotic is known to be teratogenic\textsuperscript{15} |
| **Disadvantages**: High resistance rates limit its use as a single agent. Resistance to ampicillin in E. coli in European countries and Canada averaged 29.8%, but was high as 53.9% in Spain.\textsuperscript{16} Malaysia and Tanzania reported rates of resistance of E. coli to ampicillin of 48% and 17%, respectively.\textsuperscript{17,18} Pharmacokinetic changes of pregnancy decrease plasma concentrations of β-lactams by up to 50%. |
| **Cephalixin**                              | **Advantages**: No evidence of teratogenicity\textsuperscript{19} |
| **Disadvantages**: Penicillins and cephalosporins are sometimes associated with allergic and at times anaphylactic reactions. Cephalixin is not active against Enterococcus spp.\textsuperscript{19} |
| **Trimethoprim-Sulfamethoxazole**           | **Disadvantages**: Based on observational and case-control data there have been concern raised over the use of Trimethoprim-Sulfamethoxazole in the first trimester due to an association with neural tube and other birth defects. The evidence in the literature is however, mixed. In theory, sulfonamides should also be avoided after 32 weeks gestation because of their associated toxicity in newborns. Sulfonamides could displace bilirubin from albumin-binding sites and could cause severe jaundice leading to kernicterus. Practical evidence of the risk, however, is sparse. Actual haemolytic anaemia is another complication that could occur in newborn with glucose-6-phosphate dehydrogenase deficiency.\textsuperscript{20} Overall rates of resistance of E. coli to trimethoprim sulfamethoxazole among urinary tract isolates across the US was 16.8% but was as high as 33.3% in some states.\textsuperscript{21} |

---


Shruti Prabha. Urinary Tract Infections in Pregnancy
A multicenter, double-blind randomized, placebo controlled noninferiority trial was conducted in Thailand, Philippines, Vietnam, and Argentina to evaluate whether a 1-day nitrofurantoin regimen is as effective as a 7-day regimen in eradicating asymptomatic bacteriuria during pregnancy. Escherichia coli was the most common potentially pathogenic organism detected, with prevalence approaching 50%. Bacteriologic cure rates at treatment day 14 were 75.7% and 86.2% for 1 day and 7-day regimens, respectively. Since the 7-day regimen of nitrofurantoin was found to be significantly more effective than the 1-day regimen, the authors recommended that women with asymptomatic bacteriuria in pregnancy should receive the standard 7-day regimen.

CONCLUSION
Symptomatic and asymptomatic bacteriuria is commonly encountered in pregnant women. Untreated asymptomatic bacteriuria is a risk factor for pyelonephritis in pregnancy. E. coli is the most common etiologic agent in asymptomatic and symptomatic bacteriuria of pregnancy. The condition can be detected by urine culture, which should be performed at least once during early pregnancy (12-16 weeks). For treatment, nitrofurantoin has been found to be the antibiotic of choice because it achieves therapeutic levels only in the urine and is safe during pregnancy.

REFERENCES

Table 5: Treatment regimens for urinary tract infections in pregnancy.

| Oral antibiotics | 1. Nitrofurantoin 100 mg QID (4 times a day) or Nitrofurantoin MR (modified release twice daily) is the treatment of choice. |
| Intravenous antibiotics | 2. Ampicillin 500 mg (MD (6 hourly). |
| (For pyelonephritis). | 3. Amoxicillin 500 mg TDS (3 times a day 8 hourly). |
| | 4. Cephalexin 250 mg TDS. |
| | 5. Fosfomycin one 3g satchet |
| Duration of Treatment | 1. Asymptomatic bacteriuria: 3-5 day. |
| | 2. Acute cystitis: 7 day. |
| | 3. Acute Pyelonephritis: 14 day (IV X 2 days; oral X 12 days). |
| For Treatment Failure | 1. Nitrofurantoin 100 mg four times daily for 21 days. |
| | 2. Nitrofurantoin 100 mg OD (once a day) at bed time. |
| | 3. Cephalexin 250 mg OD. |
| | 4. Amoxicillin 250 mg OD. |

Source of Support: Nil.

Conflict of Interest: None Declared.

Copyright: © the author(s) and publisher. IJMRP is an official publication of Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882. This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.